Cantor Fitzgerald reiterates Gilead Sciences stock rating on HIV drug approval

Cantor Fitzgerald reiterated an Overweight rating on Gilead Sciences and a $155 price target, implying upside from the current $124.30 share price. The FDA accepted Gilead’s 300 mg once-weekly oral Yeztugo for HIV PrEP, with a PDUFA date of Feb. 2, 2027, potentially making it the first longer-acting oral regimen in the setting. The company also highlighted a 2.64% dividend yield and 11 consecutive years of dividend growth, while shares are down 7.5% month-to-date.

Analysis

This reads less like an immediate earnings catalyst and more like a long-duration multiple support event: the market is getting visibility on a broader PrEP franchise architecture, which matters because HIV prevention is one of the few areas where payer economics, adherence, and brand trust can compound across formulations. The key second-order effect is that a single branded platform spanning oral, semiannual, and annual dosing reduces commercial fragmentation and raises switching costs, making it harder for future entrants to win purely on convenience.

The competitive implication is more important than the headline approval timing. A once-weekly oral option can serve as the default bridge for patients not ready for injections, which may slow the conversion of incumbency from existing oral regimens to emerging long-acting injectables. That creates a window where GILD can defend share before the market fully sorts out whether the winner is the most convenient, the least invasive, or the easiest to reimburse; this is especially relevant if buy-and-bill channels remain sluggish, since an oral option sidesteps those frictions and keeps access in retail channels.

The main risk is that the market may be pricing in a cleaner rollout than is likely between now and the 2027 action date. In the interim, the stock can still trade on prescription momentum, payer adoption, and broader HIV growth rather than regulatory optionality, so any disappointment on uptake could compress the multiple even if the product thesis is intact. Conversely, if the oral label expands adherence and keeps patients within the Gilead ecosystem, the valuation rerating could come from steadier cash flow durability rather than a single launch spike.

The contrarian read is that consensus is treating this as a binary approval story when the real asset is channel control: GILD is building a menu that can match patient preference across lifecycle stages, which is more defensible than chasing one “best” dosage form. That makes the stock interesting as a quality compounder with downside partly buffered by capital returns, but it also means upside is likely to be stair-stepped over 12-24 months, not repriced overnight.

Key Decisions for Investors

• Buy GILD on weakness into the next 4-8 weeks; use the post-news pullback to build a core long with a 12-18 month horizon. Risk/reward improves if the market remains focused on the 2027 date and ignores the platform economics.
• Pair trade: long GILD / short a basket of smaller HIV-prevention exposed names or single-product biotech comparables over 6-12 months. Thesis is that branded channel control and multiple dosing formats should widen share capture versus narrower franchise models.
• Sell near-dated GILD covered calls against a core long into any pre-catalyst strength. The risk is capped upside from a slow-burn catalyst path, while dividend yield provides carry while waiting.
• If available, consider a call spread in GILD with maturities beyond 12 months rather than a simple outright call. This aligns with the long regulatory runway and limits premium bleed if prescription data stays muted.
• Use any evidence of faster oral prescription uptake or payer acceptance as the trigger to add, not the approval headline itself. The trade works best when the market sees conversion metrics improve before the formal FDA action date.